Per-oral Endoscopic Myotomy (POEM) in Patients with Postfundplication Dysphagia
VADYSMA
A Prospective Pilot Trial of Per-oral Endoscopic Myotomy (POEM) in Patients with Postfundplication Dysphagia (VADYSMA Trial)
1 other identifier
interventional
30
2 countries
2
Brief Summary
Laparoscopic fundoplication represents the standard antireflux procedure, when conservative measures fail. However, any type of fundoplication may be accompanied by adverse events. Postfundoplication dysphagia (PFD) may hamper results of anti-reflux surgery. Endoscopic pneumatic dilation has been considered as the first line treatment option for persistent PFD. However, studies have not confirmed its effectiveness in this indication. Peroral endoscopic myotomy (POEM) became a standard treatment for the management of esophageal achalasia and moreover has also been assessed in a small cohort of patients with refractory PFD and some patients achieved significant treatment success. We plan to perform a prospective international cohort multicenter study assessing the efficacy of POEM in patients with persistent and severe PFD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2025
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 10, 2025
CompletedFirst Posted
Study publicly available on registry
March 12, 2025
CompletedStudy Start
First participant enrolled
April 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
March 12, 2025
February 1, 2025
2.2 years
February 10, 2025
March 6, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Efficacy and safety of POEM in patients with postfundoplication dysfagia
The primary outcome will be proportion of patients with treatment success defined as Eckardt score ≤ 2 and its decrease by at least 1 point after POEM at 6 months
6 months
Secondary Outcomes (11)
Eckardt score
At baseline and after 3, 6 and 12 months
Mellow - Pinkas score
At baseline and after 3, 6 and 12 months
PAGI-QOL score (Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life)
At baseline and after 3, 6 and 12 months
GERD-RHQL score (Gastroesophageal Reflux Disease Health-related Quality of Life)
At baseline and after 3, 6 and 12 months
Integrated Relaxation Pressure (IRP)
At baseline and after 6 months
- +6 more secondary outcomes
Study Arms (1)
POEM arm
EXPERIMENTALPatients, who will undergo peroral endoscopic myotomy for postfundoplication dysphagia
Interventions
All procedures will be performed by an experienced endoscopist, with a sufficient experience in "third space" endoscopy (at least 100 POEMs) under general anesthesia (internal preoperative examination is necessary) with a high-definition endoscope, fitted with a plastic distal attachment. Before the procedure, the patients will be administered intravenous antibiotics. Exclusively CO2 will be used for insufflation. POEM will be performed in a similar way as in patients with achalasia - the procedure consists of 4 steps: (1) mucosal incision and tunnel entry, (2) submucosal tunneling, (3) myotomy, and (4) closure of the mucosal entry with endoscopic clips or other closure devices. Perioperative protocol might differ according the usual way of performing POEM in a given center.
Eligibility Criteria
You may qualify if:
- Patients after laparoscopic fundoplication procedure by Nissen (total, 360°), Dor (anterior, 180°) or Toupet (posterior, 270°) for gastroesophageal reflux disease no later than 10 years before enrolment.
- Refractory (\> 6 months) and severe dysphagia after fundoplication procedure defined as an Eckardt score ≥3 and Mellow - Pinkas score ≥2 at baseline.
- X-ray (contrasted radiographic examination of the esophagus) characterized by both: a.) tapered narrowing of the distal esophagus and GEJ; b.) partial/total stagnation of the contrast solution above the GEJ
- Endoluminal planimetry: EGJ-DI \< 3 mm2/mmHg (with 40ml)
- Age above 18 years
- Signed informed consent form
You may not qualify if:
- No previous attempt with at least one prokinetic drug
- Previous esophageal myotomy (open, laparoscopic or endoscopic)
- Primary esophageal motility disorder (achalasia etc.)
- Active erosive esophagitis
- Active peptic ulcer disease
- Esophageal stricture (peptic, malignant, other)
- Partial or complete supradiaphragmatic migration of the wrap and/or stomach (Hinder Type III - IV), Large hiatal hernia more than 5 cm
- Known eosinophilic esophagitis
- Severe coagulopathy
- Esophageal or gastric varices
- Advanced liver cirrhosis (Child B or Child C)
- Pregnancy or puerperium
- Malignant or pre-malignant esophageal diseases (dysplasia): patients with a history of such disease after its cure are eligible for enrolment
- Any other condition, which in the opinion of the investigator would interfere with study requirements
- Known gastroparesis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
St. Anne's University Hospital Brno, Czech Republic
Brno, 60200, Czechia
University Hospital Trnava
Trnava, 91701, Slovakia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Gastroenterology and hepatology department
Study Record Dates
First Submitted
February 10, 2025
First Posted
March 12, 2025
Study Start
April 1, 2025
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2027
Last Updated
March 12, 2025
Record last verified: 2025-02